ImmuCell Corp. (ICCC)
9.75
+0.15
(+1.56%)
USD |
NASDAQ |
Oct 02, 16:00
ImmuCell Price to Book Value : 2.822 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.822 |
| October 01, 2026 | 2.779 |
| September 30, 2026 | 2.837 |
| September 29, 2026 | 2.877 |
| September 28, 2026 | 2.86 |
| September 25, 2026 | 2.873 |
| September 24, 2026 | 2.886 |
| September 23, 2026 | 2.892 |
| September 22, 2026 | 2.892 |
| September 21, 2026 | 2.932 |
| September 18, 2026 | 2.880 |
| September 17, 2026 | 2.889 |
| September 16, 2026 | 2.782 |
| September 15, 2026 | 2.773 |
| September 14, 2026 | 2.811 |
| September 11, 2026 | 2.851 |
| September 10, 2026 | 2.870 |
| September 09, 2026 | 2.869 |
| September 08, 2026 | 2.848 |
| September 04, 2026 | 2.866 |
| September 03, 2026 | 2.895 |
| September 02, 2026 | 2.895 |
| September 01, 2026 | 2.872 |
| August 31, 2026 | 2.834 |
| August 28, 2026 | 2.877 |
| Date | Value |
|---|---|
| August 27, 2026 | 2.901 |
| August 26, 2026 | 2.901 |
| August 25, 2026 | 2.848 |
| August 24, 2026 | 2.848 |
| August 21, 2026 | 2.912 |
| August 20, 2026 | 2.921 |
| August 19, 2026 | 2.932 |
| August 18, 2026 | 2.825 |
| August 17, 2026 | 2.808 |
| August 14, 2026 | 2.909 |
| August 13, 2026 | 3.155 |
| August 12, 2026 | 3.178 |
| August 11, 2026 | 3.170 |
| August 10, 2026 | 3.176 |
| August 07, 2026 | 3.184 |
| August 06, 2026 | 3.19 |
| August 05, 2026 | 3.112 |
| August 04, 2026 | 3.204 |
| August 03, 2026 | 3.196 |
| July 31, 2026 | 3.245 |
| July 30, 2026 | 3.202 |
| July 29, 2026 | 3.187 |
| July 28, 2026 | 3.254 |
| July 27, 2026 | 3.222 |
| July 24, 2026 | 3.193 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.628 |
| Alnylam Pharmaceuticals, Inc. | 21.70 |
| Savara, Inc. | 6.877 |
| Vericel Corp. | 5.552 |
| Biogen, Inc. | 1.723 |
Price to Book Value Related Metrics
| PE Ratio | 116.35 |
| PS Ratio | 2.887 |
| Price to Free Cash Flow | 21.01 |
| Price | 9.75 |
| Earnings Yield | 0.86% |
| Market Cap | 88.55M |
| Operating PE Ratio | 47.45 |
| Normalized PE Ratio | 70.70 |